peplexicon
Choose your depth

Context, anatomy, and key evidence

← Peptide library

somatostatin analog

Lanreotide

Published evidence · coverage incomplete
Anatomical contextAnatomy connections are not mapped yet.

No body region is highlighted until this profile has a supported anatomical connection. This does not mean the peptide has no biological effects.

Read published mechanism findings ↓

At a glance

What is it—and why does it matter?

Lanreotide is a somatostatin analog mentioned as part of the primary treatment options for ADPKD or PLD. Lanreotide (a somatostatin analog) suppresses pancreatic hormone secretion, including insulin and glucagon, which can affect glycemic control. Lanreotide, categorized as a first-generation somatostatin receptor ligand (FGSRL), was included as a comparator in the cost-effectiveness model. Lanreotide (Somatuline Depot) is contraindicated for patients with prior hypersensitivity to lanreotide, reflecting risk of allergic reactions.

Sources for this introduction: [1] [2] [3] [4]

This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.

What is it?

A molecule, not a product name.

Identity

Lanreotide is a somatostatin analog mentioned as part of the primary treatment options for ADPKD or PLD.

Sources[3]pubmedComparative Efficacy and Safety of Octreotide, Lanreotide, and Pasireotide in ADPKD and PLD: A Network Meta-analysis with Real-world Evidence from the FAERS Database.Somatostatin analogs were the primary treatment for autosomal dominant polycystic kidney disease (ADPKD) or polycystic liver disease (PLD), including octreotide, lanreotide, and pasireotide.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Somatostatin analogs were the primary treatment for autosomal dominant polycystic kidney disease (ADPKD) or polycystic liver disease (PLD), including octreotide, lanreotide, and pasireotide.”

    Comparative Efficacy and Safety of Octreotide, Lanreotide, and Pasireotide in ADPKD and PLD: A Network Meta-analysis with Real-world Evidence from the FAERS Database. · Abstract

    pubmed:42476150:260a94a8363d:260a94a8363d

How does it work?

Target, response, and disposition.

Mechanism

Lanreotide (a somatostatin analog) suppresses pancreatic hormone secretion, including insulin and glucagon, which can affect glycemic control.

Sources[2]dailymedThese highlights do not include all the information needed to use SOMATULINE DEPOT safely and effectively. See full prescribing information for SOMATULINE DEPOT.SOMATULINE®DEPOT (lanreotide) injection, for subcutaneous useInitial U.S. Approval: 2007Pharmacological studies in animals and humans show that lanreotide, like somatostatin and other somatostatin analogs, inhibits the secretion of insulin and glucagon.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Pharmacological studies in animals and humans show that lanreotide, like somatostatin and other somatostatin analogs, inhibits the secretion of insulin and glucagon.”

    These highlights do not include all the information needed to use SOMATULINE DEPOT safely and effectively. See full prescribing information for SOMATULINE DEPOT.SOMATULINE®DEPOT (lanreotide) injection, for subcutaneous useInitial U.S. Approval: 2007 · 5.2 Hyperglycemia and Hypoglycemia

    dailymed:6e4a41fd-a753-4362-87ee-8cc56ed3660d:9d28156b15e2:9d28156b15e2

Mechanism

Lanreotide shows receptor subtype selectivity, with higher affinity at SSTR2 and SSTR5 than at SSTR1/3/4, which informs its pharmacodynamic profile.

Sources[2]dailymedThese highlights do not include all the information needed to use SOMATULINE DEPOT safely and effectively. See full prescribing information for SOMATULINE DEPOT.SOMATULINE®DEPOT (lanreotide) injection, for subcutaneous useInitial U.S. Approval: 2007Lanreotide has a high affinity for human somatostatin receptors (SSTR) 2 and 5 and a reduced binding affinity for human SSTR1, 3, and 4.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Lanreotide has a high affinity for human somatostatin receptors (SSTR) 2 and 5 and a reduced binding affinity for human SSTR1, 3, and 4.”

    These highlights do not include all the information needed to use SOMATULINE DEPOT safely and effectively. See full prescribing information for SOMATULINE DEPOT.SOMATULINE®DEPOT (lanreotide) injection, for subcutaneous useInitial U.S. Approval: 2007 · 12.2 Pharmacodynamics

    dailymed:6e4a41fd-a753-4362-87ee-8cc56ed3660d:9d28156b15e2:9d28156b15e2

Mechanism

As a somatostatin analog, lanreotide inhibits pancreatic hormone secretion, including insulin and glucagon, which can affect glucose regulation.

Sources[1]dailymedThese highlights do not include all the information needed to use LANREOTIDE INJECTION safely and effectively. See full prescribing information for LANREOTIDE INJECTION.LANREOTIDE injection, for subcutaneous useInitial U.S. Approval: 2007Pharmacological studies in animals and humans show that lanreotide, like somatostatin and other somatostatin analogs, inhibits the secretion of insulin and glucagon.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Pharmacological studies in animals and humans show that lanreotide, like somatostatin and other somatostatin analogs, inhibits the secretion of insulin and glucagon.”

    These highlights do not include all the information needed to use LANREOTIDE INJECTION safely and effectively. See full prescribing information for LANREOTIDE INJECTION.LANREOTIDE injection, for subcutaneous useInitial U.S. Approval: 2007 · 5.2 Hyperglycemia and Hypoglycemia

    dailymed:11da176a-99bc-4ada-8b3f-6bd2b37a6313:b21a7b0297c9:b21a7b0297c9

What has been studied?

What the evidence says.

Comparative evidence

Combination therapy with pegvisomant plus lanreotide was included among the evaluated treatment strategies.

Sources[4]pubmedCost-effectiveness of pasireotide as second-line therapy for adult acromegaly patients from the perspective of the Brazilian Unified Health System.PAS LAR was dominant versus PEG monotherapy and in combination with LAN, generating similar health benefits (an additional 0.17 and 0.10 QALYs, respectively) and lower therapy costs (savings of -R$538,945 [-US$100,675] and -R$782,542 [-US$146,179]).
Reported result
additional 0.10 QALYs; savings of -R$782,542 [-US$146,179] (PAS LAR vs PEG + LAN)
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “PAS LAR was dominant versus PEG monotherapy and in combination with LAN, generating similar health benefits (an additional 0.17 and 0.10 QALYs, respectively) and lower therapy costs (savings of -R$538,945 [-US$100,675] and -R$782,542 [-US$146,179]).”

    Cost-effectiveness of pasireotide as second-line therapy for adult acromegaly patients from the perspective of the Brazilian Unified Health System. · RESULTS

    pubmed:42621460:dfb89c8343dd:dfb89c8343dd

Comparative evidence

Lanreotide, categorized as a first-generation somatostatin receptor ligand (FGSRL), was included as a comparator in the cost-effectiveness model.

Sources[4]pubmedCost-effectiveness of pasireotide as second-line therapy for adult acromegaly patients from the perspective of the Brazilian Unified Health System.Comparators included the FGSRLs, lanreotide (LAN) and octreotide (OCT), and PEG, as monotherapy and in combination with FGSRLs.
Source records
1
Independent studies
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Comparators included the FGSRLs, lanreotide (LAN) and octreotide (OCT), and PEG, as monotherapy and in combination with FGSRLs.”

    Cost-effectiveness of pasireotide as second-line therapy for adult acromegaly patients from the perspective of the Brazilian Unified Health System. · METHODS

    pubmed:42621460:dfb89c8343dd:dfb89c8343dd

Risks and interactions

Risks, organized for scanning.

Contraindications

A labeled contraindication for lanreotide is prior hypersensitivity to lanreotide (e.g., allergic reactions).

Sources[1]dailymedThese highlights do not include all the information needed to use LANREOTIDE INJECTION safely and effectively. See full prescribing information for LANREOTIDE INJECTION.LANREOTIDE injection, for subcutaneous useInitial U.S. Approval: 2007Lanreotide Injection is contraindicated in patients with history of a hypersensitivity to lanreotide.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Lanreotide Injection is contraindicated in patients with history of a hypersensitivity to lanreotide.”

    These highlights do not include all the information needed to use LANREOTIDE INJECTION safely and effectively. See full prescribing information for LANREOTIDE INJECTION.LANREOTIDE injection, for subcutaneous useInitial U.S. Approval: 2007 · 4 CONTRAINDICATIONS

    dailymed:11da176a-99bc-4ada-8b3f-6bd2b37a6313:b21a7b0297c9:b21a7b0297c9

Contraindications

Lanreotide (Somatuline Depot) is contraindicated for patients with prior hypersensitivity to lanreotide, reflecting risk of allergic reactions.

Sources[2]dailymedThese highlights do not include all the information needed to use SOMATULINE DEPOT safely and effectively. See full prescribing information for SOMATULINE DEPOT.SOMATULINE®DEPOT (lanreotide) injection, for subcutaneous useInitial U.S. Approval: 2007SOMATULINE DEPOT is contraindicated in patients with history of a hypersensitivity to lanreotide.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “SOMATULINE DEPOT is contraindicated in patients with history of a hypersensitivity to lanreotide.”

    These highlights do not include all the information needed to use SOMATULINE DEPOT safely and effectively. See full prescribing information for SOMATULINE DEPOT.SOMATULINE®DEPOT (lanreotide) injection, for subcutaneous useInitial U.S. Approval: 2007 · 4 CONTRAINDICATIONS

    dailymed:6e4a41fd-a753-4362-87ee-8cc56ed3660d:9d28156b15e2:9d28156b15e2

Products and regulatory status

Same ingredient. Different records.

Regulatory status

Lanreotide (Somatuline Depot) has an FDA-labeled indication for long-term management of acromegaly in patients for whom surgery/radiotherapy are ineffective or not feasible.

Sources[2]dailymedThese highlights do not include all the information needed to use SOMATULINE DEPOT safely and effectively. See full prescribing information for SOMATULINE DEPOT.SOMATULINE®DEPOT (lanreotide) injection, for subcutaneous useInitial U.S. Approval: 2007SOMATULINE DEPOT is indicated for the long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “SOMATULINE DEPOT is indicated for the long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option.”

    These highlights do not include all the information needed to use SOMATULINE DEPOT safely and effectively. See full prescribing information for SOMATULINE DEPOT.SOMATULINE®DEPOT (lanreotide) injection, for subcutaneous useInitial U.S. Approval: 2007 · 1.1 Acromegaly

    dailymed:6e4a41fd-a753-4362-87ee-8cc56ed3660d:9d28156b15e2:9d28156b15e2

Regulatory status

Lanreotide (Somatuline Depot) is labeled for adult unresectable, well/moderately differentiated, locally advanced or metastatic GEP-NETs, with the intended clinical outcome of improved progression-free survival.

Sources[1]dailymedThese highlights do not include all the information needed to use LANREOTIDE INJECTION safely and effectively. See full prescribing information for LANREOTIDE INJECTION.LANREOTIDE injection, for subcutaneous useInitial U.S. Approval: 2007Lanreotide Injection is indicated for the treatment of adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.[2]dailymedThese highlights do not include all the information needed to use SOMATULINE DEPOT safely and effectively. See full prescribing information for SOMATULINE DEPOT.SOMATULINE®DEPOT (lanreotide) injection, for subcutaneous useInitial U.S. Approval: 2007SOMATULINE DEPOT is indicated for the treatment of adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.
Source records
2
Regulatory records
2

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Lanreotide Injection is indicated for the treatment of adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.”

    These highlights do not include all the information needed to use LANREOTIDE INJECTION safely and effectively. See full prescribing information for LANREOTIDE INJECTION.LANREOTIDE injection, for subcutaneous useInitial U.S. Approval: 2007 · 1.2 Gastroenteropancreatic Neuroendocrine Tumors

    dailymed:11da176a-99bc-4ada-8b3f-6bd2b37a6313:b21a7b0297c9:b21a7b0297c9
  2. supports · Source-backed record
    “SOMATULINE DEPOT is indicated for the treatment of adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.”

    These highlights do not include all the information needed to use SOMATULINE DEPOT safely and effectively. See full prescribing information for SOMATULINE DEPOT.SOMATULINE®DEPOT (lanreotide) injection, for subcutaneous useInitial U.S. Approval: 2007 · 1.2 Gastroenteropancreatic Neuroendocrine Tumors

    dailymed:6e4a41fd-a753-4362-87ee-8cc56ed3660d:9d28156b15e2:9d28156b15e2

Regulatory status

Lanreotide Injection has an FDA-labeled indication for long-term management of acromegaly in patients who do not respond adequately to surgery/radiotherapy or cannot undergo these options.

Sources[1]dailymedThese highlights do not include all the information needed to use LANREOTIDE INJECTION safely and effectively. See full prescribing information for LANREOTIDE INJECTION.LANREOTIDE injection, for subcutaneous useInitial U.S. Approval: 2007Lanreotide Injection is indicated for the long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Lanreotide Injection is indicated for the long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option.”

    These highlights do not include all the information needed to use LANREOTIDE INJECTION safely and effectively. See full prescribing information for LANREOTIDE INJECTION.LANREOTIDE injection, for subcutaneous useInitial U.S. Approval: 2007 · 1.1 Acromegaly

    dailymed:11da176a-99bc-4ada-8b3f-6bd2b37a6313:b21a7b0297c9:b21a7b0297c9

Administration context

The practical clinical context.

Administration

Somatuline Depot (lanreotide) is administered via deep subcutaneous injection, with administration intended to be performed by a healthcare professional.

Sources[2]dailymedThese highlights do not include all the information needed to use SOMATULINE DEPOT safely and effectively. See full prescribing information for SOMATULINE DEPOT.SOMATULINE®DEPOT (lanreotide) injection, for subcutaneous useInitial U.S. Approval: 2007For deep subcutaneous injection only.SOMATULINE DEPOT is intended for administration by a healthcare provider.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “For deep subcutaneous injection only.SOMATULINE DEPOT is intended for administration by a healthcare provider.”

    These highlights do not include all the information needed to use SOMATULINE DEPOT safely and effectively. See full prescribing information for SOMATULINE DEPOT.SOMATULINE®DEPOT (lanreotide) injection, for subcutaneous useInitial U.S. Approval: 2007 · 2.1 Important Administration Instructions

    dailymed:6e4a41fd-a753-4362-87ee-8cc56ed3660d:9d28156b15e2:9d28156b15e2

Dose records

The labeled regimen for GEP-NETs is lanreotide 120 mg via deep subcutaneous injection once every 4 weeks.

Sources[1]dailymedThese highlights do not include all the information needed to use LANREOTIDE INJECTION safely and effectively. See full prescribing information for LANREOTIDE INJECTION.LANREOTIDE injection, for subcutaneous useInitial U.S. Approval: 2007The recommended dosage of Lanreotide Injection is 120 mg administered every 4 weeks by deep subcutaneous injection.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The recommended dosage of Lanreotide Injection is 120 mg administered every 4 weeks by deep subcutaneous injection.”

    These highlights do not include all the information needed to use LANREOTIDE INJECTION safely and effectively. See full prescribing information for LANREOTIDE INJECTION.LANREOTIDE injection, for subcutaneous useInitial U.S. Approval: 2007 · 2.1 Recommended Dosage

    dailymed:11da176a-99bc-4ada-8b3f-6bd2b37a6313:b21a7b0297c9:b21a7b0297c9

Dose records

Lanreotide (Somatuline Depot) dosage forms include three fixed-dose prefilled syringe strengths, enabling administration of 60 mg, 90 mg, or 120 mg per injection volume specified.

Sources[2]dailymedThese highlights do not include all the information needed to use SOMATULINE DEPOT safely and effectively. See full prescribing information for SOMATULINE DEPOT.SOMATULINE®DEPOT (lanreotide) injection, for subcutaneous useInitial U.S. Approval: 2007Injection: 60 mg/0.2 mL, 90 mg/0.3 mL, and 120 mg/0.5 mL sterile, single-dose, prefilled syringes fitted with an automatic safety system (attached retractable needle and needle guard).
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “Injection: 60 mg/0.2 mL, 90 mg/0.3 mL, and 120 mg/0.5 mL sterile, single-dose, prefilled syringes fitted with an automatic safety system (attached retractable needle and needle guard).”

    These highlights do not include all the information needed to use SOMATULINE DEPOT safely and effectively. See full prescribing information for SOMATULINE DEPOT.SOMATULINE®DEPOT (lanreotide) injection, for subcutaneous useInitial U.S. Approval: 2007 · 3 DOSAGE FORMS AND STRENGTHS

    dailymed:6e4a41fd-a753-4362-87ee-8cc56ed3660d:9d28156b15e2:9d28156b15e2

Dose records

The labeled regimen for carcinoid syndrome is lanreotide 120 mg administered by deep subcutaneous injection every 4 weeks.

Sources[1]dailymedThese highlights do not include all the information needed to use LANREOTIDE INJECTION safely and effectively. See full prescribing information for LANREOTIDE INJECTION.LANREOTIDE injection, for subcutaneous useInitial U.S. Approval: 2007The recommended dosage of Lanreotide Injection is 120 mg administered every 4 weeks by deep subcutaneous injection.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The recommended dosage of Lanreotide Injection is 120 mg administered every 4 weeks by deep subcutaneous injection.”

    These highlights do not include all the information needed to use LANREOTIDE INJECTION safely and effectively. See full prescribing information for LANREOTIDE INJECTION.LANREOTIDE injection, for subcutaneous useInitial U.S. Approval: 2007 · 2.1 Recommended Dosage

    dailymed:11da176a-99bc-4ada-8b3f-6bd2b37a6313:b21a7b0297c9:b21a7b0297c9

Dose records

The labeled initial regimen for acromegaly is lanreotide 90 mg administered via deep subcutaneous injection every 4 weeks for 3 months before subsequent adjustment.

Sources[1]dailymedThese highlights do not include all the information needed to use LANREOTIDE INJECTION safely and effectively. See full prescribing information for LANREOTIDE INJECTION.LANREOTIDE injection, for subcutaneous useInitial U.S. Approval: 2007The recommended starting dosage of Lanreotide Injection is 90 mg given via the deep subcutaneous route, at 4-week intervals for 3 months.
Source records
1
Regulatory records
1

Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.

Exact passages, locators, and provenance
  1. supports · Source-backed record
    “The recommended starting dosage of Lanreotide Injection is 90 mg given via the deep subcutaneous route, at 4-week intervals for 3 months.”

    These highlights do not include all the information needed to use LANREOTIDE INJECTION safely and effectively. See full prescribing information for LANREOTIDE INJECTION.LANREOTIDE injection, for subcutaneous useInitial U.S. Approval: 2007 · 2.1 Recommended Dosage

    dailymed:11da176a-99bc-4ada-8b3f-6bd2b37a6313:b21a7b0297c9:b21a7b0297c9

Research status + gaps

What still needs better answers?

  • No publishable claim yet for: effect, interaction, safety
  • 72 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (42), assurance_score_below_0.72 (24), current_regulatory_source_required (12), extraction_ambiguity (55), extraction_confidence_not_high (4), high_risk_requires_regulatory_or_two_independent_sources (26), no_direct_support (66)

These are the limits of this profile, not an exhaustive list of scientific uncertainties.

References + discovery

Open the records yourself.

  1. These highlights do not include all the information needed to use LANREOTIDE INJECTION safely and effectively. See full prescribing information for LANREOTIDE INJECTION.LANREOTIDE injection, for subcutaneous useInitial U.S. Approval: 2007 ↗

    dailymed · published 2024-09-01 · retrieved 2026-09-04T19:34:25Z

  2. These highlights do not include all the information needed to use SOMATULINE DEPOT safely and effectively. See full prescribing information for SOMATULINE DEPOT.SOMATULINE®DEPOT (lanreotide) injection, for subcutaneous useInitial U.S. Approval: 2007 ↗

    dailymed · published 2024-10-11 · retrieved 2026-09-04T19:34:27Z

  3. Comparative Efficacy and Safety of Octreotide, Lanreotide, and Pasireotide in ADPKD and PLD: A Network Meta-analysis with Real-world Evidence from the FAERS Database. ↗

    pubmed · published 2026-07-20 · retrieved 2026-08-21T17:03:42Z

  4. Cost-effectiveness of pasireotide as second-line therapy for adult acromegaly patients from the perspective of the Brazilian Unified Health System. ↗

    pubmed · published 2026-01-01 · retrieved 2026-08-21T17:03:42Z

Publication history and provenance

Version 7 · Automated assessment · 2026-09-04T19:34:27Z

23c3779c6271e6385bd6b4a27c8207247da1d0f1386db66126f602d20eb0ef79